Human artificial chromosome vector
View Patent ↗The present invention provides a human artificial chromosome vector comprising a gene encoding the human antibody heavy chain, a gene encoding the human antibody light chain, and a gene encoding IgM heavy chain constant region derived from a nonhuman animal; and being capable of producing a human antibody with a higher efficiency when the vector is introduced into an animal. By immunizing the animal produced using a human artificial chromosome vector of the present invention with a desired antigen, a large quantity of human polyclonal antibodies can be supplied.
1. A human artificial chromosome (HAC) vector, wherein the HAC comprises:
a) a gene encoding a human antibody heavy chain, wherein the gene encoding the human antibody heavy chain encodes at least a human IgG (γ) heavy chain, a human IgA (α) heavy chain or both human IgG and IgA heavy chains,
b) a gene encoding a human antibody light chain, and
c) a gene encoding a chimeric IgM (μ) heavy chain constant region, wherein the gene encoding the chimeric IgM heavy chain constant region comprises a human IgM heavy chain constant region gene substituted with DNA encoding an ungulate IgM heavy chain constant region gene; wherein the gene encoding the chimeric IgM heavy chain constant region encodes constant region (CH) domains CH1, CH2, CH3 and CH4, and transmembrane domains (TM) TM1 and TM2; and wherein the encoded human CH4, TM1 and TM2 domains are completely substituted with the encoded CH4, TM1 and TM2 domains of the ungulate IgM heavy chain constant region gene.
2. The HAC vector of claim 1 , wherein the encoded human CH3 domain is completely substituted with the encoded CH3 domain of an ungulate IgM heavy chain constant region.
3. The HAC vector of claim 2 , wherein the encoded CH2 domain is a chimeric ungulate-human CH2 domain.
4. The HAC vector of claim 2 wherein the encoded human CH2 domain is completely substituted with the encoded CH2 domain of an ungulate IgM heavy chain constant region gene.
5. The HAC vector of claim 4 , wherein the encoded CH1 domain is a chimeric ungulate-human CH1 domain.
6. The HAC vector of claim 4 , wherein the encoded human CH1 domain is completely substituted with the encoded CH1 domain of an ungulate IgM heavy chain constant region gene.
7. The HAC vector of claim 1 , wherein the gene encoding the human antibody heavy chain in part a) encodes human IgA (α), human IgD (δ), human IgE (ε), human IgG (Υ) and human IgM (μ) heavy chains.
8. The HAC vector of claim 1 , wherein the gene encoding the human antibody heavy chain in part a) comprises a human chromosome 14 fragment comprising the 14q32 region.
9. The HAC vector of claim 1 , wherein the gene encoding a human antibody light chain in part b) encodes either kappa (κ) human antibody light chain or lambda (λ) human antibody light chain, or both κand λ human antibody light chains.
10. The HAC vector of claim 1 , wherein the HAC vector further comprises a gene encoding a human antibody surrogate light chain selected from the group consisting of VpreB1, VpreB3, and λ5.
11. The HAC vector of claim 1 , wherein the ungulate genes are bovine genes.
12. The HAC vector of claim 2 , wherein the ungulate genes are bovine genes.
13. The HAC vector of claim 3 , wherein the ungulate genes are bovine genes.
14. The HAC vector of claim 4 , wherein the ungulate genes are bovine genes.
15. The HAC vector of claim 5 , wherein the ungulate genes are bovine genes.
16. The HAC vector of claim 6 , wherein the ungulate genes are bovine genes.
17. An ungulate having the HAC vector of claim 1 .
18. The ungulate of claim 17 , wherein the ungulate is a bovine.
19. A method for producing a human antibody, comprising:
a) administering a target antigen into a transgenic ungulate having the HAC vector of claim 1 ;
b) accumulating the human antibody specific to the antigen in serum of the transgenic ungulate, and
c) recovering the human antibody specific to the antigen from the serum;
wherein the ungulate produces a serum concentration of at least 1,000 ug/mL of human IgG.
20. The method of claim 19 , wherein the ungulate immunoglobulin M (μ) heavy-chains are inactivated (IGHM −/− and IGHML1 − ) .
21. The method of claim 19 , wherein the ungulate is a bovine.
22. A method for producing a human antibody, comprising:
a) administering a target antigen into a transgenic bovine having the HAC vector of claim 1 ;
b) accumulating the human antibody specific to the antigen in serum of the transgenic bovine, and
c) recovering the human antibody specific to the antigen from the serum.